Mallinckrodt completes sale of its intrathecal therapy business to piramal enterprises limited

Mallinckrodt plc , a leading specialty pharmaceutical company, announced it has closed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited’s subsidiary in the U.K., Piramal Critical Care, for approximately $203 million, including fixed and contingent consideration.

The company’s Intrathecal Therapy business markets products for the treatment of spasticity via intrathecal drug delivery, including the key asset Gablofen® (baclofen injection).

Mallinckrodt’s divesture of this business is aligned with the company’s ongoing focus on driving return on invested capital, and contributes to the strategic transformation of the company.
“This action is another example of the strategic evolution of our portfolio, and will free resources for investing in our growth platforms in autoimmune and rare diseases and hospital therapies,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. “Our Intrathecal Therapy business is an excellent fit for Piramal Critical Care, and is the best solution to meet patient needs.”
The approximately $203 million transaction will consist of $171 million of fixed consideration of which 10%, or $17 million, will be paid at closing, and an additional $154 million will be paid on the first anniversary of the close date. The remaining total consideration of up to $32 million is contingent, based on the gross profit of the Gablofen products in 2018 and 2019.
Gablofen, a product approved by the U.S. Food and Drug Administration (FDA) for use in management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above, is the only FDA-approved baclofen in prefilled syringes and factory-sealed vials.
About Gablofen  
Gablofen is indicated for use in the management of severe spasticity of cerebral or spinal origin. Approved by the FDA in late 2010, Gablofen is a branded, AP-rated alternative for Lioresal® Intrathecal (baclofen injection) and is listed in the FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
About Mallinckrodt  
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com .
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CONTACTS 
Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
Media 
Rhonda Sciarra
Senior Communications Manager
908-238-6765
Meredith Fischer 
Chief Public Affairs Officer
314-654-3318